Paul Francis Reid

US Patent:

7758894, Jul 20, 2010

Filed:

Nov 6, 2006

Appl. No.:

11/592896

Inventors:

Paul F. Reid - Plantation FL, US
Laurence N. Raymond - Plantation FL, US

Assignee:

Receptopharm, Inc. - Plantation FL

International Classification:

A61K 35/58
A61K 38/17

US Classification:

424542, 514 12

Abstract:

Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the immune cells to these detoxified proteins yields a strong response in the innate immune reaction that represents the immune systems initial response to infectious agents. Of particular relevance is the marked increase in the expression of genes associated with the production of gamma interferon, a potent antiviral agent and regulator of the immune response. The ability to induce this strong innate response has significant application to those with weakened immune systems where their ability to fight infection has been compromised. It also has the potential application to act as a method to protect individuals from contagious infectious agents as a substitute for anti-viral vaccines.

US Patent:

7902152, Mar 8, 2011

Filed:

Dec 19, 2006

Appl. No.:

11/642312

Inventors:

Paul F. Reid - Plantation FL, US
Zheng Hong Qin - Plantation FL, US

Assignee:

Receptopharm, Inc. - Plantation FL

International Classification:

A61K 38/16

US Classification:

514 121, 424520, 424542

Abstract:

A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.

US Patent:

8034777, Oct 11, 2011

Filed:

Sep 23, 2004

Appl. No.:

10/947434

Inventors:

Paul F. Reid - Plantation FL, US
Laurence N. Raymond - Plantation FL, US

Assignee:

Receptopharm, Inc. - Plantation FL

International Classification:

A61K 38/00

US Classification:

514 179, 514 11, 514 214, 514 2192

Abstract:

The invention comprises a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin. Alpha-neurotoxin solution, such as cobratoxin, is filter sterilized to remove bacteria. It is modified using HO. Any suitable preservative for parenteral administration can be employed such as methyl paraben, benzalkonium chloride or metacreosol. It is preferred that the composition is administered every other day or daily. The composition may be administered orally, subcutaneously, intramuscularly or intravenously. Parenterally, either subcutaneous or intramuscular injection is preferred.

US Patent:

20030211465, Nov 13, 2003

Filed:

Nov 12, 2002

Appl. No.:

10/292164

Inventors:

David Mundschenk - Dania FL, US
Paul Reid - Hollywood FL, US

International Classification:

C12Q001/70
A61K038/19
C07K014/52

US Classification:

435/005000, 424/085100, 530/351000

Abstract:

A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term “immunokine” is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptides can be included where applicable (e.g., for in vitro use).

US Patent:

20060045875, Mar 2, 2006

Filed:

Sep 2, 2004

Appl. No.:

10/934594

Inventors:

Paul Reid - Plantation FL, US

International Classification:

A61K 38/48
C07K 14/47

US Classification:

424094630, 530300000

Abstract:

The present invention provides a composition of matter and a method of using the composition for treating and preventing of retroviral infections of mammalian cells. It includes identification of Crotalus beta-neurotoxins as capable of preventing HIV infection and replication in that cell and a retroviral composition which can be administered in-vivo for the treatment of HIV infection. The retrovirus is selected from the group consisting of Lentiviruses (HIV-1, HIV-2, SIV, EIAV, BIV, and FIV). In addition, crotoxin can effect changes to the expression of HIV receptor proteins and/or cellular cofactors homologous to their target receptors.

US Patent:

20060088858, Apr 27, 2006

Filed:

Sep 2, 2005

Appl. No.:

11/217713

Inventors:

Paul Reid - Plantation FL, US
Laurence Raymond - Plantation FL, US

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435006000, 435005000

Abstract:

The present invention relates to a class of proteins, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and equine acquired immunodeficiency virus (EAIV). The method of treatment comprises administering to the subject a disease mitigating amount of a detoxified modified venom composition.

US Patent:

20070148159, Jun 28, 2007

Filed:

Dec 22, 2005

Appl. No.:

11/313377

Inventors:

Paul Reid - Plantation FL, US
Zheng Qin - Malden MA, US

International Classification:

A61K 38/48
A61K 31/60

US Classification:

424094640, 514165000

Abstract:

A method of producing analgesia and enhancing analgesia is disclosed. The method includes administering a beta-neurotoxin that is characterized by its ability to bind to pre- and postsynaptic receptors resulting in the inhibition of neurotransmission.

US Patent:

20080081048, Apr 3, 2008

Filed:

Oct 2, 2006

Appl. No.:

11/540862

Inventors:

Laurence Raymond - Plantation FL, US
Paul Reid - Plantation FL, US

International Classification:

A61K 39/08
C07K 14/195

US Classification:

4242391, 530350

Abstract:

The invention provides improved methods of making compositions comprising detoxified neurotropically active modified neurotoxins derived from snake venom, and compositions made using these methods. The compositions are useful for the treatment of a wide variety of neurological and viral diseases.